Welcome to the CGTA Research Group
Our name stands for “CNS Gene therapy Translation Acceleration.”
Our goal is to bring gene therapies for rare Central Nervous System diseases into clinical trials and use as quickly and efficiently as possible. Our first project is focused on developing a gene therapy for Huntington’s disease.
Our grant application to the National Institute of Neurological Diseases and Stroke (NINDS) was received in good order in June, 2019, and will be reviewed by the Chronic Dysfunction and Integrative Neurodegeneration Study Section on October 15, 2019.
We are in the process of preparing a grant application for submission to NINDS, regarding huntingtin-lowering. This application will be responsive to the reviews of our latest application (which received positive reviews, but not a sufficiently good priority score to make the funding cut), and also recent findings about the effects of huntingtin-lowering in animals. See the literature review by Kaemmerer and Grondin, just published this month.